Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
These regulatory developments will significantly impact the clinical availability and accessibility of both agents for patients requiring obesity treatment
352(a) and (bb)), which prohibit false or misleading labeling and advertising of drug products
2024 Oct 14;120(12):1427-1441
1,2 This rising prevalence of obesity brings significant costs to the healthcare system, estimated to be up to $172 billion in annual expenditures
2006 Dec;291(6):E1290-4
US$ 23.68
US$ 27.96
US$ 25.66
US$ 27.53
US$ 25.80
US$ 26.20
US$ 26.54
US$ 21.33
